COVID-19 vaccines do carry a small, measurable increase in the risk of Bell’s palsy, the sudden temporary paralysis of one side of the face. Large population studies across multiple countries have consistently found the risk rises modestly in the weeks after vaccination, though the absolute numbers remain low and the increase is far smaller than the facial palsy risk associated with catching COVID-19 itself. The story beneath the headlines is more nuanced than either “vaccines cause Bell’s palsy” or “there is no connection,” and the details matter for anyone weighing their personal risk.
What the Population Studies Actually Show
Several large-scale studies have moved the question well beyond anecdotal case reports. A nationwide study in South Korea covering 2021 and 2022 found that within 28 days of any COVID-19 vaccine dose, the risk of facial palsy was about 12% higher than expected, with an incidence rate ratio of 1.12. The signal was clearest after the first and second doses combined, with no detectable increase after a third dose.1Emerging Infectious Diseases. Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022 An Israeli population-based study comparing Bell’s palsy rates in vaccinated people against 2019 background rates found that the Pfizer-BioNTech vaccine was associated with a roughly 36% higher-than-expected rate of Bell’s palsy after the first dose, though the increase after the second dose was smaller and not statistically firm.2The Lancet Regional Health – Europe. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell’s palsy: a population-based study
To put those percentages into absolute terms: the Israeli study found the highest additional risk in women aged 65 and older, and even in that group the extra cases amounted to roughly 4.5 per 100,000 vaccinated people. For the general population, you are looking at single-digit extra cases per hundred thousand. That is real, but it is not common.
Which Vaccines Are Involved
The signal is not limited to one vaccine technology. The South Korean data, which covered both mRNA and viral vector vaccines, found increased facial palsy risk with both. Recipients of at least one mRNA vaccine dose had an incidence rate ratio of 1.11, while those who received only viral vector vaccines showed a somewhat higher ratio of 1.37.3Emerging Infectious Diseases. Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022
The inactivated-virus platform has also drawn attention. A Hong Kong case-control study found that CoronaVac, an inactivated COVID-19 vaccine, carried a statistically significant increased risk of Bell’s palsy, while the BNT162b2 mRNA vaccine’s risk in the same population did not reach statistical significance.4The Lancet Infectious Diseases. Bell’s palsy following vaccination with CoronaVac (inactivated SARS-CoV-2 vaccine) and BNT162b2 (mRNA COVID-19 vaccine): a case series and nested case-control study Case reports have also documented facial palsy following the AstraZeneca viral vector vaccine.5International Medical Case Reports Journal. Lower Motor Neuron Facial Palsy Following COVID-19 Infection and COVID-19 AZD1222 Vaxzervria (AstraZeneca) Vaccine Administration: Two Case Reports In short, no major vaccine platform has been clearly exempt. The effect size differs between platforms and studies, but the general pattern of a modest increase appears across all of them.
It is worth noting that Bell’s palsy has been observed as a rare side effect of other vaccines historically. An early Lancet commentary pointed out that the intranasal influenza vaccine had a known association with Bell’s palsy, and that the original Pfizer and Moderna phase 3 trials collectively saw seven Bell’s palsy cases among roughly 40,000 vaccine-arm participants compared to one in the placebo group.6The Lancet Infectious Diseases. Bell’s palsy and SARS-CoV-2 vaccines That imbalance was what first flagged the possible connection, though seven cases out of 40,000 people was too small to be definitive on its own.
COVID-19 Infection Poses a Bigger Facial Palsy Risk Than the Vaccines
This is the comparison that often gets lost in media coverage. A systematic review and meta-analysis published in JAMA Otolaryngology found that Bell’s palsy was roughly three times more common after a COVID-19 infection than after COVID-19 vaccination, with a relative risk of 3.23.7JAMA Otolaryngology–Head & Neck Surgery. Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-analysis The authors noted that this actually suggests vaccines play a protective role by reducing your overall exposure to the much larger risk that comes with the virus itself.
South Korean data reinforced this picture. Background Bell’s palsy rates in South Korea rose during the pandemic years, from about 23 per 100,000 annually in 2008 to 32.5 per 100,000 during 2021–2022. A separate retrospective study from the same country found that COVID-19 infection itself was associated with a 20% increased risk of Bell’s palsy in vaccinated individuals and an 84% increased risk in unvaccinated individuals.8Emerging Infectious Diseases. Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022 So unvaccinated people who catch COVID face a substantially higher chance of developing facial palsy than vaccinated people face from either the vaccine or a breakthrough infection.
Who Seems to Be at Higher Risk
The Israeli study found the strongest association in older adults, particularly women. After the first vaccine dose, women aged 45 to 64 had roughly 71% more Bell’s palsy cases than expected, and women aged 65 and older had about 2.5 times the expected rate.9The Lancet Regional Health – Europe. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell’s palsy: a population-based study Men aged 65 and older also showed elevated rates, though their increase was smaller and bordered on statistical significance.
Interestingly, the Hong Kong case series showed a different demographic skew. Among clinically confirmed Bell’s palsy cases following CoronaVac, roughly two-thirds were male with a median age of about 58, while cases following BNT162b2 also leaned male with a slightly younger median age of about 48.10The Lancet Infectious Diseases. Bell’s palsy following vaccination with CoronaVac (inactivated SARS-CoV-2 vaccine) and BNT162b2 (mRNA COVID-19 vaccine): a case series and nested case-control study These differences likely reflect the demographics of who was being vaccinated in each country at the time, as well as the relatively small case numbers that make it hard to draw firm demographic conclusions. What the data broadly agree on is that the risk tends to be higher in older adults.
People With a History of Bell’s Palsy
If you have had Bell’s palsy before, the question of whether vaccination could trigger a recurrence is understandably front of mind. The Israeli study tracked over 7,500 adults with a prior history of Bell’s palsy who received the Pfizer vaccine. Among them, four developed a recurrence within 21 days of the first dose and ten within 30 days of the second dose. After the second dose, the rate was about twice what would be expected based on pre-pandemic recurrence patterns, and that increase was statistically significant.11The Lancet Regional Health – Europe. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell’s palsy: a population-based study
Individual case reports add texture to this finding. One published case described a 57-year-old woman who had experienced three prior episodes of Bell’s palsy and developed another episode less than 36 hours after her second Pfizer dose. She responded to prednisone treatment as she had in her previous episodes.12Brain, Behavior, & Immunity – Health. Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy Another report documented a 61-year-old man who developed Bell’s palsy on opposite sides of his face after each vaccine dose: the first episode began five hours after the first injection, and the second occurred two days after the second injection.13BMJ Journals. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses
These numbers are still small in absolute terms. Even in the group with prior Bell’s palsy, the recurrence risk after the second dose was about 142 per 100,000 over 30 days, meaning more than 99.8% of people with a history of Bell’s palsy did not experience a recurrence. But the doubling of the expected rate is worth a conversation with your doctor, particularly if your episodes have been frequent or severe.
Why This Might Happen
No one has pinned down a definitive mechanism, but several plausible theories have converged. The leading explanation involves molecular mimicry: the immune response stimulated by the vaccine’s spike protein or viral vector components may accidentally target proteins on the facial nerve that resemble the vaccine antigen, activating autoreactive immune cells that cause nerve inflammation.14Annals of Medicine and Surgery. Bell’s palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19
For viral vector vaccines specifically, researchers have proposed that antibodies produced against the vector’s viral proteins may cross-react with myelin antigens on peripheral nerves, causing demyelination, the stripping away of the nerve’s insulating sheath. A related pathway involves bystander activation, where the strong immune response triggered by the vaccine inadvertently switches on immune cells that happen to be reactive against the body’s own nerve tissue.15Emerging Infectious Diseases. Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022
For mRNA vaccines, a slightly different angle has been proposed. The combination of mRNA and the lipid nanoparticles used to deliver it may trigger innate immune activation and the production of interferon proteins. Interferon therapy in other medical contexts has been associated with facial nerve palsy, so this pathway could explain how mRNA vaccines in particular might provoke the condition.16The Lancet Infectious Diseases. Bell’s palsy following vaccination with CoronaVac (inactivated SARS-CoV-2 vaccine) and BNT162b2 (mRNA COVID-19 vaccine): a case series and nested case-control study
Another early theory suggested that the immune activation from vaccination could reactivate latent herpesviruses, which are a known trigger of Bell’s palsy in the general population. However, a study that looked for herpesvirus shedding in the throat before and after Pfizer vaccination found no evidence of increased reactivation one week later, which weakens this particular hypothesis.17PubMed Central. Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
How Post-Vaccine Bell’s Palsy Presents and Resolves
The timing and severity of post-vaccine facial palsy vary widely. A systematic review of 51 published cases found that the onset ranged from as early as three hours to as late as two months after vaccination. Most cases, roughly 88%, occurred after the first dose rather than the second. Symptoms ranged from mild facial weakness to complete paralysis of one side of the face.18Annals of Medicine and Surgery. Development of facial palsy following COVID-19 vaccination: A systematic review
One unusual finding from that review was that a majority of the reported cases, about 53%, involved bilateral facial palsy, meaning both sides of the face were affected. Bilateral Bell’s palsy is quite rare in the general population, occurring in only about 1–2% of all Bell’s palsy cases. This overrepresentation in post-vaccine reports is striking, though it could partly reflect a reporting bias: unusual presentations are more likely to be published as case reports than typical one-sided cases.
The prognosis is generally good. In the same review, about 76% of patients had partially recovered by the time of their last follow-up (including some still undergoing treatment), and about 22% had recovered completely. Treatment follows the same approach used for any Bell’s palsy episode: corticosteroids to reduce nerve inflammation, sometimes combined with antiviral medication. Emergency presentations are typically managed with intravenous steroids, while milder cases receive a tapering course of oral prednisolone over roughly two weeks.19Annals of Medicine and Surgery. Bell’s palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19
What MRI Scans Show
When imaging is performed in post-vaccine Bell’s palsy cases, the findings look similar to Bell’s palsy from any other cause. Contrast-enhanced brain MRI typically shows enhancement of the affected facial nerve within the internal auditory canal, reflecting inflammation and swelling of the nerve.20PubMed Central. Bilateral facial nerve palsy after COVID 19 vaccination In some reported cases, MRI has revealed involvement beyond the facial nerve. One case showed enhancement of the facial, trigeminal, and oculomotor nerves simultaneously, suggesting that the inflammatory process can occasionally be broader than classic Bell’s palsy.21PubMed Central. Multiple cranial nerve palsies following COVID-19 vaccination-Case report
A case report involving a teenager who developed facial nerve paralysis alongside sensory loss in two branches of the trigeminal nerve three days after his first Pfizer dose illustrates this broader pattern. His MRI and clinical findings suggested a more generalized cranial nerve inflammation rather than isolated Bell’s palsy. Over six weeks of follow-up, his symptoms gradually improved with oral steroids, though the authors were careful to note that temporal association does not prove causation.22BMJ Case Reports. Concurrent facial and trigeminal nerve palsies in a child following COVID-19 vaccination with the Pfizer vaccine
Media Coverage and the Perception Gap
The public conversation around vaccines and Bell’s palsy has been louder than the data would justify. An analysis of Google Trends data from Australia found that search interest in Bell’s palsy spiked dramatically during the mRNA vaccine rollout in 2021 and 2022, reaching an unusually high relative search volume in August 2022. The researchers attributed this to disproportionate and sometimes inaccurate media coverage, noting that the reported Bell’s palsy rates at that time likely reflected the normal background rate in the community rather than a vaccine-driven spike.23Australian Journal of Otolaryngology. Analysis of Google Trends data on facial paralysis as a proxy of public interest
This gap between the data and the public perception of the data is a familiar pattern in vaccine safety discussions. Bell’s palsy is frightening when it happens: you wake up unable to move half your face, unable to fully close one eye, sometimes unable to taste food properly. A condition that visceral will always generate outsized anxiety relative to its statistical rarity, and headlines about vaccines causing facial paralysis land differently than headlines about vaccines causing a mild, temporary increase in an already-rare condition. The absolute risk increase of a few extra cases per 100,000 vaccinated people, set against the backdrop of roughly 25–35 cases per 100,000 people that occur every year anyway, is not the sort of nuance that survives the jump from journal article to social media post.
For anyone who developed Bell’s palsy shortly after vaccination, the experience was real and the timing was not necessarily a coincidence. The evidence supports a genuine, small increase in risk. But the same evidence also shows that most cases resolve, that COVID-19 infection itself carries a considerably larger facial palsy risk, and that the absolute numbers involved are small enough that they do not change the overall risk-benefit calculation for the vast majority of people. The exception worth flagging is people with a history of recurrent Bell’s palsy, for whom the decision deserves an individualized conversation with a clinician rather than a blanket reassurance.